secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-10-08T11:04:33+00:00
Accession:  0001650664-26-000093
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Editas receives Australian approval to initiate Phase 1/2 Strive trial of EDIT-401 in HeFH
--------------------------------------------------------------------------------

- Australia's TGA and HREC cleared the Phase 1/2 Strive trial of EDIT-401; a submission is also under review in New Zealand, with five trial sites selected across both countries.
- Strive is two-part: Part 1 single ascending dose, open-label; Part 2 single-dose, randomized, placebo-controlled. Initial safety/tolerability data expected Q1 2027. Topline later in 2027.
- Preclinical data showed ~90% or greater mean reduction in LDL-C, Lp(a) and ApoB in non-human primates; ~90% LDL-C reduction was maintained over 10 months.
- Editas will present EDIT-401 durability data at AHA Scientific Sessions on Nov 8, 2026, in Chicago; CMO Dan Ory, M.D. is the presenter.
- Editas remains on track to begin patient dosing in 2026 and plans to complete Part 1 enrollment with topline safety and efficacy results later in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000093/0001650664-26-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000093/edit-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001650664-26-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer